BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6183037)

  • 1. Converting enzyme inhibition: implications for renal perfusion and function.
    Hollenberg NK
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():73-9. PubMed ID: 6183037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal response to angiotensin-converting enzyme inhibition.
    Hollenberg NK
    Am J Cardiol; 1982 Apr; 49(6):1425-9. PubMed ID: 6176107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal hemodynamics in essential and renovascular hypertension. Influence of captopril.
    Hollenberg NK
    Am J Med; 1984 May; 76(5B):22-8. PubMed ID: 6328983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin and the renal circulation in hypertension.
    Hollenberg NK; Williams GH
    Circulation; 1988 Jun; 77(6 Pt 2):I59-63. PubMed ID: 3286047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade.
    Laragh JH; Case DB; Wallace JM; Keim H
    Fed Proc; 1977 Apr; 36(5):1781-7. PubMed ID: 191300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
    Packer M
    Circulation; 1988 Jun; 77(6 Pt 2):I64-73. PubMed ID: 2967129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
    Seymour AA; Asaad MM; Lanoce VM; Langenbacher KM; Fennell SA; Rogers WL
    J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure.
    Faxon DP; Creager MA; Halperin JL; Bernard DB; Ryan TJ
    Am J Med; 1984 May; 76(5B):104-10. PubMed ID: 6203405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.
    Hollenberg NK; Swartz SL; Passan DR; Williams GH
    N Engl J Med; 1979 Jul; 301(1):9-12. PubMed ID: 221809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the renal nerves and angiotensin II in the renal function curve.
    Golin R; Genovesi S; Castoldi G; Wijnmaalen P; Protasoni G; Zanchetti A; Stella A
    Arch Ital Biol; 1999 Aug; 137(4):289-97. PubMed ID: 10443320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M; Brunner HR
    Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity.
    Zusman RM
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):13-23. PubMed ID: 3037886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the angiotensin converting enzyme (ACE) inhibitor, captopril, on the cardiovascular, endocrine, and renal responses to furosemide in conscious lambs.
    de Wildt SN; Smith FG
    Can J Physiol Pharmacol; 1997 Apr; 75(4):263-70. PubMed ID: 9196851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.
    Seymour AA; Sheldon JH; Smith PL; Asaad M; Rogers WL
    J Pharmacol Exp Ther; 1994 Apr; 269(1):263-70. PubMed ID: 8169834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and pharmacology of angiotensin converting enzyme inhibitors.
    Antonaccio MJ
    J Pharmacol; 1983; 14 Suppl 3():29-45. PubMed ID: 6323887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased vascular responsiveness produced by angiotensin-converting enzyme inhibitors in the rat isolated kidney.
    Chiba S; Quilley CP; McGiff JC
    Hypertension; 1982; 4(3 Pt 2):80-5. PubMed ID: 6175573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium sensitive hypertension: renal and adrenal non-modulation in its pathogenesis.
    Hollenberg NK; Williams GH
    Kidney; 1988 Nov; 21(3):13-8. PubMed ID: 11538850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting enzyme inhibition and the kidney.
    Meggs LG; Hollenberg NK
    Hypertension; 1980; 2(4):551-7. PubMed ID: 6156899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.